Clinical Trials Logo

Central Serous Chorioretinopathy clinical trials

View clinical trials related to Central Serous Chorioretinopathy.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05679180 Withdrawn - Clinical trials for Central Serous Chorioretinopathy

Navigated Microsecond Laser for Chronic Central Serous Chorioretinopathy: MICROPULSE

MICROPULSE
Start date: May 11, 2023
Phase: N/A
Study type: Interventional

MICROPULSE study aims to evaluate the efficacy of navigated microsecond laser (nMSL) for chronic central serous chorioretinopathy (CSCR).

NCT ID: NCT01256580 Withdrawn - Myopia Clinical Trials

Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD

CNV
Start date: August 2010
Phase: N/A
Study type: Interventional

Anti-VEGF therapy has been proven efficacious for the wet (neovascular) form of macular degeneration and may be beneficial for the treatment of choroidal neovascularization (CNV) due to other causes. The limitation of this type of treatment is the necessity for frequent intraocular injections. The purpose of this study is to determine if using anti-VEGF therapy in combination with photodynamic therapy can reduce the number of treatments needed with monotherapy while achieving similar visual results. There are ongoing multicenter trials evaluating combination therapy in patients with wet AMD but no similar trial for patients with CNV due to non-AMD causes. Therefore, in this study the investigators will focus on patients with CNV not due to AMD.

NCT ID: NCT00418431 Withdrawn - Clinical trials for Central Serous Chorioretinopathy

Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy

Start date: April 2006
Phase: Phase 2/Phase 3
Study type: Interventional

Central serous chorioretinopathy (CSC) has been known since it was first described by Von Graefe and termed "idiopathic detachment of the macula" in 1866, is a well-characterized disorder leading to serous neurosensory elevation of the central macula. The acute form of the disease is associated with focal leakage at the level of the retinal pigment epithelium (RPE) demonstrated with fluorescein angiography (FA). The disorder is self-limited in the majority of patients, who also regain excellent vision. Occasionally, the neurosensory detachment persists and leads to pigment epithelial and photoreceptor damage with visual impairment. The purpose of this clinical study is report the use of intravitreal bevacizumab is a new option in the treatment of the chronic or recurrent CSC.